Your browser doesn't support javascript.
loading
Discovery of indazole-pyridinone derivatives as a novel class of potent and selective MNK1/2 kinase inhibitors that protecting against endotoxin-induced septic shock.
Dreas, Agnieszka; Kucwaj-Brysz, Katarzyna; Pyziak, Karolina; Kulesza, Urszula; Wincza, Ewelina; Fabritius, Charles-Henry; Michalik, Kinga; Gabor-Worwa, Ewelina; Golas, Aniela; Milik, Mariusz; Masiejczyk, Magdalena; Majewska, Eliza; Pysniak, Kazimiera; Wójcik-Trechcinska, Urszula; Sandowska-Markiewicz, Zuzanna; Brzózka, Krzysztof; Ostrowski, Jerzy; Rzymski, Tomasz; Mikula, Michal.
Afiliación
  • Dreas A; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland. Electronic address: agnieszka.dreas@ryvu.com.
  • Kucwaj-Brysz K; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Pyziak K; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Kulesza U; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Wincza E; Selvita S.A., Bobrzynskiego 14, 30-348, Kraków, Poland.
  • Fabritius CH; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Michalik K; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Gabor-Worwa E; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Golas A; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Milik M; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Masiejczyk M; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Majewska E; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Pysniak K; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland.
  • Wójcik-Trechcinska U; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland.
  • Sandowska-Markiewicz Z; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland.
  • Brzózka K; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Ostrowski J; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland; Department of Gastroenterology, Hepatology and Clinical Oncology, Centre of Postgraduate Medical Education, 02-781, Warsaw, Poland.
  • Rzymski T; Ryvu Therapeutics S.A., H. L. Sternbacha 2, 30-394, Kraków, Poland.
  • Mikula M; Department of Genetics, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781, Warsaw, Poland. Electronic address: michal.mikula@pib-nio.pl.
Eur J Med Chem ; 213: 113057, 2021 Mar 05.
Article en En | MEDLINE | ID: mdl-33303237
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridonas / Choque Séptico / Proteínas Serina-Treonina Quinasas / Péptidos y Proteínas de Señalización Intracelular / Inhibidores de Proteínas Quinasas / Factores Inmunológicos / Indazoles Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Piridonas / Choque Séptico / Proteínas Serina-Treonina Quinasas / Péptidos y Proteínas de Señalización Intracelular / Inhibidores de Proteínas Quinasas / Factores Inmunológicos / Indazoles Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2021 Tipo del documento: Article